AstraZeneca's CAPItello Phase 3 Trial For Truqap (Capivasertib) Combined With Paclitaxel In Locally Advanced/Metastatic Triple-negative Breast Cancer Did Not Meet The Dual Primary Endpoints Of Improvement In Overall Survival Versus Paclitaxel Plus Placebo
AstraZeneca's CAPItello Phase 3 Trial For Truqap (Capivasertib) Combined With Paclitaxel In Locally Advanced/Metastatic Triple-negative Breast Cancer Did Not Meet The Dual Primary Endpoints Of Improvement In Overall Survival Versus Paclitaxel Plus Placebo
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.